Kiesewetter H, Jung F, Birk A, Spitzer S
Department of Clinical Hemostasiology and Transfusion Medicine, University of the Saarland, Homburg-Saar, Germany.
Int Angiol. 1994 Mar;13(1):1-4.
Patients with peripheral arterial occlusive disease (PAOD) and marked atherosclerosis often present concomitant diseases like coronary heart disease, cerebral circulatory disorders or arterial hypertension. Thus, the extent of hypervolemia is limited in case of an infusion treatment without venesection. Therefore, it was tested whether a hypervolemic hemodilution without venesection is superior to a dilution with venesection in multimorbid patients suffering from PAOD stage II. The colloidal iso-molar solution used was Haes 200/0.5 6%. Both forms of hemodilution were significantly superior compared to a control group well hydrated with cristalloid saline solution; all groups practised walking exercise twice a week over a period of one hour. However, hypervolemic hemodilution without venesection was only slightly better than the dilution with venesection. The walking distance in the group without venesection increased by 68.6 m (36.7%) in the group without venesection, by 59.0 (30.4%) in the group with venesection and by 33.6 m (20.1%) in the control group. The results show that the decision to perform a hyperor isovolemic hemodilution should depend on the volume tolerance of each patient.
患有外周动脉闭塞性疾病（PAOD）且伴有明显动脉粥样硬化的患者，常伴有冠心病、脑循环障碍或动脉高血压等疾病。因此，在不进行放血的输液治疗中，高血容量的程度是有限的。所以，研究人员测试了在患有II期PAOD的多病患者中，不放血的高血容量血液稀释是否优于放血的血液稀释。所使用的胶体等渗溶液是贺斯200/0.5 6%。与用晶体盐溶液充分补液的对照组相比，两种血液稀释方式均有显著优势；所有组每周进行两次一小时的步行锻炼。然而，不放血的高血容量血液稀释仅比放血的血液稀释稍好一点。不放血组的步行距离增加了68.6米（36.7%），放血组增加了59.0米（30.4%），对照组增加了33.6米（20.1%）。结果表明，决定进行高血容量或等血容量血液稀释应取决于每个患者的容量耐受性。
